Angiotensin II antagonists in heart failure – clinical trials review

Marcin Grabowski; Krzysztof J. Filipiak; Grzegorz Opolski

Abstract

5/2005 vol. 8

Angiotensin II antagonists in heart failure – clinical trials review

Marcin Grabowski

,

Krzysztof J. Filipiak

,

Grzegorz Opolski

Przew Lek 2005; 5: 78-82

Online publish date: 2005/07/15

View full text

AMA

Grabowski M, Filipiak K, Opolski G. Angiotensin II antagonists in heart failure – clinical trials review. Przewodnik Lekarza/Guide for GPs. 2005:78-82.

APA

Grabowski, M., Filipiak, K., & Opolski, G. (2005). Angiotensin II antagonists in heart failure – clinical trials review. Przewodnik Lekarza/Guide for GPs, 78-82.

Chicago

Grabowski, Marcin, Krzysztof J. Filipiak, and Grzegorz Opolski. 2005. "Angiotensin II antagonists in heart failure – clinical trials review". Przewodnik Lekarza/Guide for GPs: 78-82.

Harvard

Grabowski, M., Filipiak, K., and Opolski, G. (2005). Angiotensin II antagonists in heart failure – clinical trials review. Przewodnik Lekarza/Guide for GPs, pp.78-82.

MLA

Grabowski, Marcin et al. "Angiotensin II antagonists in heart failure – clinical trials review." Przewodnik Lekarza/Guide for GPs, 2005, pp. 78-82.

Vancouver

Grabowski M, Filipiak K, Opolski G. Angiotensin II antagonists in heart failure – clinical trials review. Przewodnik Lekarza/Guide for GPs. 2005:78-82.

Angiotensin II receptor antagonists act by a different mechanism than the angiotensin converting enzyme inhibitors, although both reduce the stimulation of angiotensin II receptors. Trials of these agents have been conducted to determine whether they have a comparable benefit in patients with heart failure. The clinical data that have addressed the use of angiotensin II receptor antagonists in patients with heart failure will be reviewed here.

Keywords

angiotensin II antagonist, heart failure, clinical trials

Integrated with